Share Price and Basic Stock Data
Last Updated: November 22, 2025, 9:38 am
| PEG Ratio | 3.65 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Rossari Biotech Ltd operates in the specialty chemicals sector and has shown remarkable growth in revenue over recent years. The company reported sales of ₹1,656 Cr for the fiscal year ending March 2023, reflecting a significant increase from ₹1,483 Cr in March 2022. This upward trajectory continued, with sales rising to ₹1,831 Cr in March 2024 and projected at ₹2,080 Cr for March 2025. The trailing twelve months (TTM) sales stood at ₹2,222 Cr, indicating a robust demand for its products. Quarterly sales also demonstrated a solid performance, with ₹483 Cr recorded in September 2023, up from ₹411 Cr in June 2023. This consistent growth trend positions Rossari as a key player in the specialty chemicals market, capitalizing on increasing industrial demand and expanding its product portfolio.
Profitability and Efficiency Metrics
Rossari Biotech has displayed commendable profitability metrics, with a net profit of ₹137 Cr in FY 2025, up from ₹107 Cr in FY 2023. The operating profit margin (OPM) stood at 12% for the same fiscal year, indicative of efficient cost management in a competitive landscape. The company’s interest coverage ratio (ICR) was reported at an impressive 15.11x, demonstrating its ability to comfortably meet interest obligations, while return on equity (ROE) and return on capital employed (ROCE) were recorded at 12.2% and 15.8%, respectively. These figures are competitive within the chemicals sector, where average ROE typically falls between 10% to 15%. However, the cash conversion cycle (CCC) of 101 days suggests room for improvement in operational efficiency, particularly in inventory and receivables management.
Balance Sheet Strength and Financial Ratios
As of March 2025, Rossari Biotech’s balance sheet reflects a solid financial position, with total reserves amounting to ₹1,240 Cr and borrowings at ₹353 Cr. The company’s debt-to-equity ratio stood at 0.15, indicating a conservative leverage approach which is favorable for maintaining financial stability. The price-to-book value (P/BV) ratio of 2.82x suggests that the market values the company’s equity favorably compared to its book value. Additionally, the current ratio of 1.94 and quick ratio of 1.28 demonstrate healthy liquidity, enabling the company to meet its short-term obligations. The company’s ability to maintain a low level of debt while ensuring growth in assets positions it well against potential financial downturns.
Shareholding Pattern and Investor Confidence
The shareholding structure of Rossari Biotech indicates a strong level of promoter confidence, with promoters holding 68.18% of the equity as of March 2025. This stable ownership reflects a commitment to long-term growth strategies. Institutional investors, including Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs), collectively held around 20.88%, with DIIs increasing their stake to 18.18%. This trend is a positive indicator, as institutional investment often signals confidence in the company’s future prospects. The public shareholding stood at 10.95%, revealing a broad base of retail investors. However, the gradual decline in FII participation from 8.63% in December 2022 to 2.70% in March 2025 could raise concerns about international investor sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Rossari Biotech is positioned for further growth, driven by strong revenue trends and solid profitability metrics. However, risks such as fluctuating raw material costs and potential regulatory changes in the chemicals sector could impact margins. Additionally, the company’s relatively high cash conversion cycle highlights the need for operational efficiency improvements. Should Rossari successfully enhance its inventory management and receivables collection, it could bolster profitability and investor confidence. Conversely, failure to address these operational challenges may hinder growth. Overall, Rossari Biotech presents a compelling investment case, underpinned by a strong balance sheet and growth trajectory, while remaining vigilant to external market risks.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Rossari Biotech Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 425 Cr. | 46.1 | 86.7/42.6 | 26.4 | 20.5 | 0.87 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 35.2 Cr. | 71.7 | 103/56.0 | 16.8 | 89.6 | 1.40 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 46.2 Cr. | 680 | 988/600 | 21.3 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,679 Cr. | 81.2 | 111/78.0 | 24.4 | 22.0 | 0.62 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 656 Cr. | 263 | 453/241 | 23.6 | 93.8 | 0.95 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,884.24 Cr | 741.86 | 63.68 | 182.93 | 0.42% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 435 | 425 | 389 | 406 | 411 | 483 | 464 | 473 | 490 | 498 | 513 | 580 | 544 |
| Expenses | 377 | 369 | 335 | 352 | 353 | 420 | 400 | 409 | 425 | 432 | 448 | 510 | 476 |
| Operating Profit | 58 | 57 | 54 | 55 | 58 | 64 | 64 | 64 | 65 | 66 | 65 | 69 | 68 |
| OPM % | 13% | 13% | 14% | 13% | 14% | 13% | 14% | 13% | 13% | 13% | 13% | 12% | 12% |
| Other Income | 1 | 1 | 1 | 3 | 2 | 1 | 4 | 1 | 1 | 1 | 1 | 2 | 2 |
| Interest | 5 | 8 | 5 | 4 | 6 | 5 | 4 | 3 | 4 | 4 | 5 | 6 | 6 |
| Depreciation | 15 | 16 | 16 | 16 | 14 | 15 | 15 | 16 | 15 | 15 | 18 | 18 | 18 |
| Profit before tax | 39 | 34 | 35 | 37 | 39 | 45 | 48 | 46 | 47 | 48 | 42 | 48 | 46 |
| Tax % | 26% | 29% | 26% | 22% | 26% | 26% | 28% | 25% | 26% | 27% | 25% | 28% | 27% |
| Net Profit | 29 | 24 | 26 | 29 | 29 | 33 | 34 | 34 | 35 | 35 | 32 | 34 | 34 |
| EPS in Rs | 5.21 | 4.34 | 4.66 | 5.25 | 5.30 | 5.97 | 6.23 | 6.18 | 6.32 | 6.39 | 5.73 | 6.22 | 6.07 |
Last Updated: August 1, 2025, 1:10 pm
Below is a detailed analysis of the quarterly data for Rossari Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 544.00 Cr.. The value appears to be declining and may need further review. It has decreased from 580.00 Cr. (Mar 2025) to 544.00 Cr., marking a decrease of 36.00 Cr..
- For Expenses, as of Jun 2025, the value is 476.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 510.00 Cr. (Mar 2025) to 476.00 Cr., marking a decrease of 34.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 68.00 Cr.. The value appears to be declining and may need further review. It has decreased from 69.00 Cr. (Mar 2025) to 68.00 Cr., marking a decrease of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 12.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.00%.
- For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Interest, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Depreciation, as of Jun 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 46.00 Cr.. The value appears to be declining and may need further review. It has decreased from 48.00 Cr. (Mar 2025) to 46.00 Cr., marking a decrease of 2.00 Cr..
- For Tax %, as of Jun 2025, the value is 27.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Mar 2025) to 27.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 34.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 34.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 6.07. The value appears to be declining and may need further review. It has decreased from 6.22 (Mar 2025) to 6.07, marking a decrease of 0.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:33 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 516 | 600 | 709 | 1,483 | 1,656 | 1,831 | 2,080 | 2,222 |
| Expenses | 438 | 495 | 586 | 1,299 | 1,433 | 1,581 | 1,815 | 1,948 |
| Operating Profit | 78 | 105 | 124 | 184 | 223 | 250 | 265 | 274 |
| OPM % | 15% | 17% | 17% | 12% | 13% | 14% | 13% | 12% |
| Other Income | 1 | 4 | 9 | 13 | 6 | 8 | 5 | 7 |
| Interest | 3 | 4 | 3 | 13 | 22 | 19 | 18 | 22 |
| Depreciation | 12 | 17 | 23 | 48 | 63 | 60 | 67 | 73 |
| Profit before tax | 63 | 88 | 107 | 136 | 144 | 178 | 185 | 186 |
| Tax % | 28% | 26% | 25% | 28% | 26% | 26% | 26% | |
| Net Profit | 46 | 65 | 80 | 98 | 107 | 131 | 136 | 137 |
| EPS in Rs | 103.82 | 12.86 | 15.45 | 17.74 | 19.45 | 23.66 | 24.63 | 24.68 |
| Dividend Payout % | 0% | 4% | 3% | 3% | 3% | 2% | 2% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 41.30% | 23.08% | 22.50% | 9.18% | 22.43% | 3.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | -18.23% | -0.58% | -13.32% | 13.25% | -18.61% |
Rossari Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 12% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 12% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -14% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 13% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 1:10 pm
Balance Sheet
Last Updated: November 9, 2025, 2:50 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 10 | 10 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 119 | 277 | 398 | 794 | 904 | 1,037 | 1,174 | 1,240 |
| Borrowings | 8 | 67 | 0 | 8 | 74 | 119 | 218 | 353 |
| Other Liabilities | 118 | 118 | 152 | 442 | 375 | 401 | 482 | 484 |
| Total Liabilities | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,088 |
| Fixed Assets | 74 | 94 | 181 | 607 | 585 | 578 | 598 | 630 |
| CWIP | 3 | 22 | 0 | 1 | 16 | 47 | 140 | 247 |
| Investments | 0 | 18 | 0 | 36 | 51 | 63 | 84 | 20 |
| Other Assets | 173 | 338 | 379 | 611 | 712 | 880 | 1,063 | 1,190 |
| Total Assets | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,088 |
Below is a detailed analysis of the balance sheet data for Rossari Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,240.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,174.00 Cr. (Mar 2025) to 1,240.00 Cr., marking an increase of 66.00 Cr..
- For Borrowings, as of Sep 2025, the value is 353.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 218.00 Cr. (Mar 2025) to 353.00 Cr., marking an increase of 135.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 484.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 482.00 Cr. (Mar 2025) to 484.00 Cr., marking an increase of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,088.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,886.00 Cr. (Mar 2025) to 2,088.00 Cr., marking an increase of 202.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 630.00 Cr.. The value appears strong and on an upward trend. It has increased from 598.00 Cr. (Mar 2025) to 630.00 Cr., marking an increase of 32.00 Cr..
- For CWIP, as of Sep 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 140.00 Cr. (Mar 2025) to 247.00 Cr., marking an increase of 107.00 Cr..
- For Investments, as of Sep 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 84.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 64.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,190.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,063.00 Cr. (Mar 2025) to 1,190.00 Cr., marking an increase of 127.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,088.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,886.00 Cr. (Mar 2025) to 2,088.00 Cr., marking an increase of 202.00 Cr..
Notably, the Reserves (1,240.00 Cr.) exceed the Borrowings (353.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 70.00 | 38.00 | 124.00 | 176.00 | 149.00 | 131.00 | 47.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 57 | 74 | 75 | 78 | 85 | 83 |
| Inventory Days | 59 | 57 | 75 | 63 | 59 | 80 | 90 |
| Days Payable | 114 | 95 | 104 | 61 | 56 | 62 | 73 |
| Cash Conversion Cycle | 6 | 19 | 46 | 76 | 80 | 103 | 101 |
| Working Capital Days | 23 | 22 | 60 | 62 | 49 | 70 | 69 |
| ROCE % | 38% | 29% | 24% | 18% | 18% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Small Cap Fund | 2,016,798 | 0.64 | 145.68 | 2,016,798 | 2025-04-22 14:12:24 | 0% |
| UTI Flexi Cap Fund | 1,915,752 | 0.54 | 138.38 | 1,915,752 | 2025-04-22 15:56:53 | 0% |
| SBI Flexi Cap Fund | 1,648,008 | 0.64 | 119.04 | 1,648,008 | 2025-04-22 15:56:53 | 0% |
| Canara Robeco Small Cap Fund | 1,067,293 | 0.93 | 85.29 | 1,067,293 | 2025-04-22 15:56:53 | 0% |
| UTI Small Cap Fund | 407,215 | 0.85 | 29.42 | 407,215 | 2025-04-22 15:56:53 | 0% |
| Bandhan Focused Equity Fund | 228,933 | 1.23 | 18.3 | 228,933 | 2025-04-22 15:56:53 | 0% |
| UTI Unit Linked Insurance Plan (ULIP) - Fifteen Year Plan | 143,597 | 0.2 | 10.37 | 143,597 | 2025-04-22 15:56:53 | 0% |
| UTI Unit Linked Insurance Plan (ULIP) - Ten Year Plan | 143,597 | 0.2 | 10.37 | 143,597 | 2025-04-22 15:56:53 | 0% |
| Nippon India Nifty Smallcap 250 Index Fund | 12,015 | 0.1 | 0.96 | 12,015 | 2025-04-22 15:56:54 | 0% |
| SBI Tax Advantage Fund - Series III | 7,000 | 1.55 | 0.51 | 7,000 | 2025-04-22 15:56:54 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 24.66 | 23.67 | 19.46 | 17.81 | 15.56 |
| Diluted EPS (Rs.) | 24.63 | 23.62 | 19.38 | 17.70 | 15.47 |
| Cash EPS (Rs.) | 36.57 | 34.56 | 30.68 | 26.19 | 19.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 214.12 | 189.65 | 165.93 | 146.25 | 78.72 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 214.12 | 189.65 | 165.93 | 146.25 | 78.72 |
| Revenue From Operations / Share (Rs.) | 375.74 | 331.35 | 300.22 | 269.36 | 136.60 |
| PBDIT / Share (Rs.) | 48.60 | 46.56 | 41.43 | 35.50 | 25.47 |
| PBIT / Share (Rs.) | 36.49 | 35.63 | 30.02 | 26.77 | 21.07 |
| PBT / Share (Rs.) | 33.27 | 32.12 | 25.97 | 24.47 | 20.49 |
| Net Profit / Share (Rs.) | 24.46 | 23.62 | 19.27 | 17.46 | 15.34 |
| NP After MI And SOA / Share (Rs.) | 24.63 | 23.66 | 19.45 | 17.74 | 15.45 |
| PBDIT Margin (%) | 12.93 | 14.05 | 13.79 | 13.17 | 18.64 |
| PBIT Margin (%) | 9.71 | 10.75 | 9.99 | 9.93 | 15.42 |
| PBT Margin (%) | 8.85 | 9.69 | 8.65 | 9.08 | 15.00 |
| Net Profit Margin (%) | 6.50 | 7.12 | 6.41 | 6.48 | 11.22 |
| NP After MI And SOA Margin (%) | 6.55 | 7.13 | 6.47 | 6.58 | 11.30 |
| Return on Networth / Equity (%) | 11.50 | 12.47 | 11.71 | 12.13 | 19.62 |
| Return on Capital Employeed (%) | 14.85 | 17.15 | 16.22 | 15.31 | 26.61 |
| Return On Assets (%) | 7.19 | 8.31 | 7.84 | 7.77 | 14.29 |
| Long Term Debt / Equity (X) | 0.08 | 0.03 | 0.03 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.15 | 0.10 | 0.08 | 0.01 | 0.00 |
| Asset Turnover Ratio (%) | 1.20 | 1.25 | 1.26 | 1.63 | 1.37 |
| Current Ratio (X) | 1.94 | 1.99 | 2.08 | 2.07 | 2.36 |
| Quick Ratio (X) | 1.28 | 1.32 | 1.54 | 1.42 | 1.73 |
| Inventory Turnover Ratio (X) | 4.08 | 5.22 | 5.70 | 6.80 | 5.66 |
| Dividend Payout Ratio (NP) (%) | 2.02 | 2.11 | 2.56 | 2.81 | 3.16 |
| Dividend Payout Ratio (CP) (%) | 1.35 | 1.44 | 1.61 | 1.88 | 2.46 |
| Earning Retention Ratio (%) | 97.98 | 97.89 | 97.44 | 97.19 | 96.84 |
| Cash Earning Retention Ratio (%) | 98.65 | 98.56 | 98.39 | 98.12 | 97.54 |
| Interest Coverage Ratio (X) | 15.11 | 13.28 | 10.24 | 15.44 | 44.20 |
| Interest Coverage Ratio (Post Tax) (X) | 8.60 | 7.74 | 5.76 | 8.60 | 27.62 |
| Enterprise Value (Cr.) | 3475.13 | 3801.34 | 3233.01 | 4985.62 | 5300.00 |
| EV / Net Operating Revenue (X) | 1.67 | 2.08 | 1.95 | 3.36 | 7.47 |
| EV / EBITDA (X) | 12.91 | 14.78 | 14.15 | 25.51 | 40.08 |
| MarketCap / Net Operating Revenue (X) | 1.61 | 2.04 | 1.98 | 3.39 | 7.60 |
| Retention Ratios (%) | 97.97 | 97.88 | 97.43 | 97.18 | 96.83 |
| Price / BV (X) | 2.82 | 3.56 | 3.59 | 6.25 | 13.18 |
| Price / Net Operating Revenue (X) | 1.61 | 2.04 | 1.98 | 3.39 | 7.60 |
| EarningsYield | 0.04 | 0.03 | 0.03 | 0.01 | 0.01 |
After reviewing the key financial ratios for Rossari Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 24.66. This value is within the healthy range. It has increased from 23.67 (Mar 24) to 24.66, marking an increase of 0.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.62 (Mar 24) to 24.63, marking an increase of 1.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 36.57. This value is within the healthy range. It has increased from 34.56 (Mar 24) to 36.57, marking an increase of 2.01.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 214.12. It has increased from 189.65 (Mar 24) to 214.12, marking an increase of 24.47.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 214.12. It has increased from 189.65 (Mar 24) to 214.12, marking an increase of 24.47.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 375.74. It has increased from 331.35 (Mar 24) to 375.74, marking an increase of 44.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 48.60. This value is within the healthy range. It has increased from 46.56 (Mar 24) to 48.60, marking an increase of 2.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 36.49. This value is within the healthy range. It has increased from 35.63 (Mar 24) to 36.49, marking an increase of 0.86.
- For PBT / Share (Rs.), as of Mar 25, the value is 33.27. This value is within the healthy range. It has increased from 32.12 (Mar 24) to 33.27, marking an increase of 1.15.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 24.46. This value is within the healthy range. It has increased from 23.62 (Mar 24) to 24.46, marking an increase of 0.84.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.66 (Mar 24) to 24.63, marking an increase of 0.97.
- For PBDIT Margin (%), as of Mar 25, the value is 12.93. This value is within the healthy range. It has decreased from 14.05 (Mar 24) to 12.93, marking a decrease of 1.12.
- For PBIT Margin (%), as of Mar 25, the value is 9.71. This value is below the healthy minimum of 10. It has decreased from 10.75 (Mar 24) to 9.71, marking a decrease of 1.04.
- For PBT Margin (%), as of Mar 25, the value is 8.85. This value is below the healthy minimum of 10. It has decreased from 9.69 (Mar 24) to 8.85, marking a decrease of 0.84.
- For Net Profit Margin (%), as of Mar 25, the value is 6.50. This value is within the healthy range. It has decreased from 7.12 (Mar 24) to 6.50, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.55. This value is below the healthy minimum of 8. It has decreased from 7.13 (Mar 24) to 6.55, marking a decrease of 0.58.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.50. This value is below the healthy minimum of 15. It has decreased from 12.47 (Mar 24) to 11.50, marking a decrease of 0.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has decreased from 17.15 (Mar 24) to 14.85, marking a decrease of 2.30.
- For Return On Assets (%), as of Mar 25, the value is 7.19. This value is within the healthy range. It has decreased from 8.31 (Mar 24) to 7.19, marking a decrease of 1.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.15. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.15, marking an increase of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.20. It has decreased from 1.25 (Mar 24) to 1.20, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has decreased from 1.99 (Mar 24) to 1.94, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.32 (Mar 24) to 1.28, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.08. This value is within the healthy range. It has decreased from 5.22 (Mar 24) to 4.08, marking a decrease of 1.14.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 2.02. This value is below the healthy minimum of 20. It has decreased from 2.11 (Mar 24) to 2.02, marking a decrease of 0.09.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 20. It has decreased from 1.44 (Mar 24) to 1.35, marking a decrease of 0.09.
- For Earning Retention Ratio (%), as of Mar 25, the value is 97.98. This value exceeds the healthy maximum of 70. It has increased from 97.89 (Mar 24) to 97.98, marking an increase of 0.09.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 98.65. This value exceeds the healthy maximum of 70. It has increased from 98.56 (Mar 24) to 98.65, marking an increase of 0.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 15.11. This value is within the healthy range. It has increased from 13.28 (Mar 24) to 15.11, marking an increase of 1.83.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.60. This value is within the healthy range. It has increased from 7.74 (Mar 24) to 8.60, marking an increase of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,475.13. It has decreased from 3,801.34 (Mar 24) to 3,475.13, marking a decrease of 326.21.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.67. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.67, marking a decrease of 0.41.
- For EV / EBITDA (X), as of Mar 25, the value is 12.91. This value is within the healthy range. It has decreased from 14.78 (Mar 24) to 12.91, marking a decrease of 1.87.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 2.04 (Mar 24) to 1.61, marking a decrease of 0.43.
- For Retention Ratios (%), as of Mar 25, the value is 97.97. This value exceeds the healthy maximum of 70. It has increased from 97.88 (Mar 24) to 97.97, marking an increase of 0.09.
- For Price / BV (X), as of Mar 25, the value is 2.82. This value is within the healthy range. It has decreased from 3.56 (Mar 24) to 2.82, marking a decrease of 0.74.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 2.04 (Mar 24) to 1.61, marking a decrease of 0.43.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Rossari Biotech Ltd:
- Net Profit Margin: 6.5%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.85% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.5% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.28
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 24.9 (Industry average Stock P/E: 63.68)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.15
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.5%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Rossari House, Golden Oak, LBS Marg, Surya Nagar, Mumbai Maharashtra 400079 | investors@rossari.com http://www.rossari.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Edward Menezes | Executive Chairman |
| Mr. Sunil Chari | Managing Director |
| Mr. Aseem Dhru | Independent Director |
| Ms. Aparna Sharma | Independent Director |
| Ms. Esha Achan | Independent Director |
| Mr. Gurudas Aras | Independent Director |
FAQ
What is the intrinsic value of Rossari Biotech Ltd?
Rossari Biotech Ltd's intrinsic value (as of 25 November 2025) is 549.67 which is 10.48% lower the current market price of 614.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,406 Cr. market cap, FY2025-2026 high/low of 885/568, reserves of ₹1,240 Cr, and liabilities of 2,088 Cr.
What is the Market Cap of Rossari Biotech Ltd?
The Market Cap of Rossari Biotech Ltd is 3,406 Cr..
What is the current Stock Price of Rossari Biotech Ltd as on 25 November 2025?
The current stock price of Rossari Biotech Ltd as on 25 November 2025 is 614.
What is the High / Low of Rossari Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Rossari Biotech Ltd stocks is 885/568.
What is the Stock P/E of Rossari Biotech Ltd?
The Stock P/E of Rossari Biotech Ltd is 24.9.
What is the Book Value of Rossari Biotech Ltd?
The Book Value of Rossari Biotech Ltd is 226.
What is the Dividend Yield of Rossari Biotech Ltd?
The Dividend Yield of Rossari Biotech Ltd is 0.08 %.
What is the ROCE of Rossari Biotech Ltd?
The ROCE of Rossari Biotech Ltd is 15.8 %.
What is the ROE of Rossari Biotech Ltd?
The ROE of Rossari Biotech Ltd is 12.2 %.
What is the Face Value of Rossari Biotech Ltd?
The Face Value of Rossari Biotech Ltd is 2.00.